evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · Kidney and Transplant

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Failure of acute rejection reversal · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).

1 finding from 1 review

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Recurrent rejection · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).

1 finding from 1 review

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).

1 finding from 1 review

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Neurological adverse effects · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).

1 finding from 1 review